[{"id":"91477ff8-142f-4402-9532-82ad52403fb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03804944","created_at":"2021-01-18T18:48:24.995Z","updated_at":"2025-02-25T14:01:36.868Z","phase":"Phase 2","brief_title":"Converting HR+ Breast Cancer Into an Individualized Vaccine","source_id_and_acronym":"NCT03804944","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-19"},{"id":"74a598bd-7a75-4999-b0f5-a6eb7255e5da","acronym":"NATASHA","url":"https://clinicaltrials.gov/study/NCT05325632","created_at":"2022-04-13T11:55:02.708Z","updated_at":"2025-02-25T13:54:21.396Z","phase":"Phase 2","brief_title":"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab \u0026 Pertuzumab","source_id_and_acronym":"NCT05325632 - NATASHA","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • HER-2 pulsed DC1"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/28/2021","start_date":" 10/28/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-12-24"},{"id":"6b26b0df-c972-4fed-adba-6edb4b098b89","acronym":"KEYNOTE-D88","url":"https://clinicaltrials.gov/study/NCT05572684","created_at":"2022-10-10T15:07:08.123Z","updated_at":"2025-02-25T16:18:14.094Z","phase":"Phase 1/2","brief_title":"A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors","source_id_and_acronym":"NCT05572684 - KEYNOTE-D88","lead_sponsor":"NextCure, Inc.","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • NC410"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 10/06/2022","start_date":" 10/06/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-12-16"},{"id":"7eb5032a-f810-48b6-80fe-022a794eb314","acronym":"","url":"https://clinicaltrials.gov/study/NCT05029999","created_at":"2021-09-01T14:53:00.539Z","updated_at":"2024-07-02T16:34:26.023Z","phase":"Phase 1","brief_title":"CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05029999","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • CDX-1140 • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 04/20/2025","primary_completion_date":" 04/20/2025","study_txt":" Completion: 04/20/2025","study_completion_date":" 04/20/2025","last_update_posted":"2024-06-14"},{"id":"be5c7d1d-dede-47c6-9803-529770521936","acronym":"IMM-101-015","url":"https://clinicaltrials.gov/study/NCT03711188","created_at":"2021-01-18T18:11:38.254Z","updated_at":"2024-07-02T16:35:07.136Z","phase":"Phase 2","brief_title":"A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma","source_id_and_acronym":"NCT03711188 - IMM-101-015","lead_sponsor":"Immodulon Therapeutics Ltd","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • IMM-101"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 12/02/2021","primary_completion_date":" 12/02/2021","study_txt":" Completion: 12/02/2021","study_completion_date":" 12/02/2021","last_update_posted":"2024-04-29"},{"id":"84233739-ed53-4cf9-9895-5c8bd3e952d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03043391","created_at":"2021-01-18T14:59:13.296Z","updated_at":"2024-07-02T16:35:10.938Z","phase":"Phase 1","brief_title":"Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children","source_id_and_acronym":"NCT03043391","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 11/07/2017","start_date":" 11/07/2017","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2024-04-08"},{"id":"2f59a817-0e8b-44c9-812f-3c051a1229d1","acronym":"LUMINOS-102","url":"https://clinicaltrials.gov/study/NCT04577807","created_at":"2021-01-18T21:51:05.215Z","updated_at":"2024-07-02T16:35:11.133Z","phase":"Phase 2","brief_title":"LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma","source_id_and_acronym":"NCT04577807 - LUMINOS-102","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" PD-L1 • BRAF • CD8","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • BRAF wild-type","tags":["PD-L1 • BRAF • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 11/17/2020","start_date":" 11/17/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-04-05"},{"id":"7737d144-a404-4582-aab1-5735a517fdd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206047","created_at":"2021-01-18T15:48:08.496Z","updated_at":"2024-07-02T16:35:11.758Z","phase":"Phase 1/2","brief_title":"Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03206047","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CTAG1B","pipe":" | ","alterations":" PD-L1 expression • CTAG1B expression","tags":["PD-L1 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • guadecitabine (SGI-110) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-03"},{"id":"c55d98dc-4757-49c8-ba40-0336728471cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03564782","created_at":"2021-01-18T17:33:07.799Z","updated_at":"2024-07-02T16:35:20.243Z","phase":"Phase 1","brief_title":"Examining Bioactivity of PVSRIPO in Invasive Breast Cancer","source_id_and_acronym":"NCT03564782","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • HER-2 expression • ER expression • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • HER-2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 06/30/2019","start_date":" 06/30/2019","primary_txt":" Primary completion: 04/11/2022","primary_completion_date":" 04/11/2022","study_txt":" Completion: 04/11/2022","study_completion_date":" 04/11/2022","last_update_posted":"2024-02-08"},{"id":"59c4433e-178c-41e8-bb65-1d9a0a1d95a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05631899","created_at":"2022-11-30T17:57:34.718Z","updated_at":"2024-07-02T16:35:20.773Z","phase":"Phase 1","brief_title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05631899","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • KRAS-EphA-2-CAR-DC"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/03/2023","start_date":" 04/03/2023","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-02-06"},{"id":"e67b207c-524d-4340-9a2e-5cbef643f117","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616248","created_at":"2021-01-19T20:33:34.730Z","updated_at":"2024-07-02T16:35:26.987Z","phase":"Phase 1","brief_title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","source_id_and_acronym":"NCT04616248","lead_sponsor":"University of Southern California","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-1140 • Hiltonol (poly-ICLC) • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/09/2023","start_date":" 01/09/2023","primary_txt":" Primary completion: 01/09/2025","primary_completion_date":" 01/09/2025","study_txt":" Completion: 01/09/2026","study_completion_date":" 01/09/2026","last_update_posted":"2023-12-06"},{"id":"03f0ece7-ebce-42e4-9045-500e01cc7916","acronym":"","url":"https://clinicaltrials.gov/study/NCT06152367","created_at":"2023-11-30T18:15:50.315Z","updated_at":"2024-07-02T16:35:27.607Z","phase":"Phase 1/2","brief_title":"Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients","source_id_and_acronym":"NCT06152367","lead_sponsor":"University of Chile","biomarkers":" IFNG • TNFA • IL10 • IL17A","pipe":" | ","alterations":" IL10 elevation","tags":["IFNG • TNFA • IL10 • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 01/30/2001","start_date":" 01/30/2001","primary_txt":" Primary completion: 10/09/2004","primary_completion_date":" 10/09/2004","study_txt":" Completion: 10/09/2004","study_completion_date":" 10/09/2004","last_update_posted":"2023-11-30"},{"id":"522ce461-bd5b-48fe-83ce-bfdef14e9b4b","acronym":"GEN001-201","url":"https://clinicaltrials.gov/study/NCT05419362","created_at":"2022-06-15T16:54:51.189Z","updated_at":"2025-02-25T16:17:49.248Z","phase":"Phase 2","brief_title":"GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer","source_id_and_acronym":"NCT05419362 - GEN001-201","lead_sponsor":"Genome \u0026 Company","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • GEN-001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 04/07/2022","start_date":" 04/07/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-17"},{"id":"02699193-e287-431a-b255-1adc890318f2","acronym":"NCI-2018-00926","url":"https://clinicaltrials.gov/study/NCT03450122","created_at":"2021-01-19T15:37:56.641Z","updated_at":"2024-07-02T16:35:33.518Z","phase":"Phase 1","brief_title":"Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma","source_id_and_acronym":"NCT03450122 - NCI-2018-00926","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B","pipe":"","alterations":" ","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/13/2018","start_date":" 09/13/2018","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/06/2022","study_completion_date":" 12/06/2022","last_update_posted":"2023-10-16"},{"id":"da239839-0e23-4db7-89fc-00f09d5fe304","acronym":"","url":"https://clinicaltrials.gov/study/NCT05631886","created_at":"2022-11-30T17:57:34.457Z","updated_at":"2024-07-02T16:35:38.927Z","phase":"Phase 1","brief_title":"Combination of CAR-DC Vaccine and ICIs in Malignant Tumors","source_id_and_acronym":"NCT05631886","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" TP53 • IL6 • IL2 • IL10","pipe":" | ","alterations":" PD-L1 expression • TP53 mutation • MSI-H/dMMR • TP53 R175H • TP53 R248Q • TP53 R273H","tags":["TP53 • IL6 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TP53 mutation • MSI-H/dMMR • TP53 R175H • TP53 R248Q • TP53 R273H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • TP53-EphA-2-CAR-DC"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/04/2023","start_date":" 07/04/2023","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2023-08-28"},{"id":"1cfc9dae-087d-4a45-888a-feae0e1a43ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02166905","created_at":"2021-01-18T10:05:33.255Z","updated_at":"2024-07-02T16:35:54.811Z","phase":"Phase 1/2","brief_title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission","source_id_and_acronym":"NCT02166905","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":"","alterations":" ","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epacadostat (INCB024360) • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/10/2014","start_date":" 10/10/2014","primary_txt":" Primary completion: 08/20/2020","primary_completion_date":" 08/20/2020","study_txt":" Completion: 08/20/2020","study_completion_date":" 08/20/2020","last_update_posted":"2023-02-24"},{"id":"591144ff-4c63-46d7-a621-a1ad32a91744","acronym":"MERECA","url":"https://clinicaltrials.gov/study/NCT02432846","created_at":"2022-08-22T14:56:54.274Z","updated_at":"2024-07-02T16:36:05.101Z","phase":"Phase 2","brief_title":"Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)","source_id_and_acronym":"NCT02432846 - MERECA","lead_sponsor":"Immunicum AB","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Intuvax (ilixadencel)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 01/31/2021","study_completion_date":" 01/31/2021","last_update_posted":"2022-08-22"},{"id":"800689f3-ecd9-4222-8b49-07a4c0b8d155","acronym":"","url":"https://clinicaltrials.gov/study/NCT03712358","created_at":"2021-01-18T18:11:54.177Z","updated_at":"2024-07-02T16:36:07.959Z","phase":"Phase 1","brief_title":"PVSRIPO for Patients With Unresectable Melanoma","source_id_and_acronym":"NCT03712358","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/26/2018","start_date":" 11/26/2018","primary_txt":" Primary completion: 03/23/2021","primary_completion_date":" 03/23/2021","study_txt":" Completion: 03/23/2021","study_completion_date":" 03/23/2021","last_update_posted":"2022-06-30"},{"id":"01e94ab7-1db7-466d-ba3b-41de1e68aa90","acronym":"PERCELLVAC","url":"https://clinicaltrials.gov/study/NCT02709616","created_at":"2022-05-27T22:55:26.156Z","updated_at":"2024-07-02T16:36:09.769Z","phase":"Phase 1","brief_title":"Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)","source_id_and_acronym":"NCT02709616 - PERCELLVAC","lead_sponsor":"Guangdong 999 Brain Hospital","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tumor antigen pulsed DC autologous cellular vaccine (personalized cellular vaccine)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 10/31/2017","primary_completion_date":" 10/31/2017","study_txt":" Completion: 06/30/2019","study_completion_date":" 06/30/2019","last_update_posted":"2022-05-27"},{"id":"9938eb41-5c2a-4e6d-a843-b0b50eb83959","acronym":"PerCellVac2","url":"https://clinicaltrials.gov/study/NCT02808364","created_at":"2022-05-27T22:55:35.734Z","updated_at":"2024-07-02T16:36:09.715Z","phase":"Phase 1","brief_title":"Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)","source_id_and_acronym":"NCT02808364 - PerCellVac2","lead_sponsor":"Guangdong 999 Brain Hospital","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tumor antigen pulsed DC autologous cellular vaccine (personalized cellular vaccine)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 10/31/2017","primary_completion_date":" 10/31/2017","study_txt":" Completion: 06/30/2019","study_completion_date":" 06/30/2019","last_update_posted":"2022-05-27"},{"id":"e5237131-82f4-4978-a8ef-0a93b269c4a7","acronym":"PerCellVac3","url":"https://clinicaltrials.gov/study/NCT02808416","created_at":"2022-05-27T22:55:36.316Z","updated_at":"2024-07-02T16:36:09.773Z","phase":"Phase 1","brief_title":"Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)","source_id_and_acronym":"NCT02808416 - PerCellVac3","lead_sponsor":"Guangdong 999 Brain Hospital","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tumor antigen pulsed DC autologous cellular vaccine (personalized cellular vaccine)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 10/31/2017","primary_completion_date":" 10/31/2017","study_txt":" Completion: 06/30/2019","study_completion_date":" 06/30/2019","last_update_posted":"2022-05-27"},{"id":"b8b377f8-f74b-4e8e-8bac-28bf811e0fc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02129075","created_at":"2021-01-18T09:52:16.035Z","updated_at":"2024-07-02T16:36:20.676Z","phase":"Phase 2","brief_title":"A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma","source_id_and_acronym":"NCT02129075","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CTAG1B • CD4 • PRAME","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B • CD4 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • Mobista (CDX-301) • Neo Vax (NEO-PV-01) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/09/2014","start_date":" 04/09/2014","primary_txt":" Primary completion: 03/28/2016","primary_completion_date":" 03/28/2016","study_txt":" Completion: 05/18/2018","study_completion_date":" 05/18/2018","last_update_posted":"2021-11-16"},{"id":"06cedc2c-5fd9-4935-a1db-659225305def","acronym":"","url":"https://clinicaltrials.gov/study/NCT05079503","created_at":"2021-10-15T14:53:04.668Z","updated_at":"2024-07-02T16:36:22.855Z","phase":"","brief_title":"Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT05079503","lead_sponsor":"Korean Cancer Study Group","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GEN-001"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/15/2021","start_date":" 12/15/2021","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 01/30/2024","study_completion_date":" 01/30/2024","last_update_posted":"2021-10-15"},{"id":"6e060b6a-aecb-4f0c-b730-57d52b351ad4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03358719","created_at":"2021-01-19T15:11:58.492Z","updated_at":"2024-07-02T16:36:23.457Z","phase":"Phase 1","brief_title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT03358719","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • azacitidine • decitabine • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 03/27/2018","start_date":" 03/27/2018","primary_txt":" Primary completion: 02/27/2020","primary_completion_date":" 02/27/2020","study_txt":" Completion: 08/25/2021","study_completion_date":" 08/25/2021","last_update_posted":"2021-10-05"}]